Forte Biosciences (FBRX) Profit After Tax (2016 - 2026)
Forte Biosciences (FBRX) reported Profit After Tax of -$22.1 million for Q1 2026, down 41.39% year-over-year from -$37.8 million in Q1 2025, and up 10.7% quarter-over-quarter from -$24.8 million in Q4 2025.
Forte Biosciences (FBRX) Profit After Tax (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Profit After Tax data on file, last reported at -$22.1 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$22.1 million, down 41.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$75.9 million (down 73.53% YoY), and the FY2025 annual result was -$69.4 million, down 95.54% from the prior year.
- Profit After Tax climbed to -$22.1 million in Q1 2026 per FBRX's latest filing, from -$24.8 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$2.6 million in Q1 2022 and troughed at -$24.8 million in Q4 2025.
- A 5-year average of -$10.1 million and a median of -$8.4 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax soared 56.13% in 2022, then plunged 246.44% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$4.9 million in 2022, then decreased by 20.4% to -$5.9 million in 2023, then fell by 21.85% to -$7.2 million in 2024, then sank by 246.44% to -$24.8 million in 2025, then increased by 10.7% to -$22.1 million in 2026.
- Business Quant data shows FBRX's Profit After Tax at -$22.1 million in Q1 2026, -$24.8 million in Q4 2025, and -$17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -24.79 Mn |
| Sep 30, 2025 | -17.68 Mn |
| Jun 30, 2025 | -11.25 Mn |
| Mar 31, 2025 | -15.66 Mn |
| Dec 31, 2024 | -7.16 Mn |
| Sep 30, 2024 | -8.39 Mn |
| Jun 30, 2024 | -12.51 Mn |
| Mar 31, 2024 | -7.42 Mn |
| Dec 31, 2023 | -5.87 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -8.90 Mn |
| Mar 31, 2023 | -6.75 Mn |
| Dec 31, 2022 | -4.88 Mn |
| Sep 30, 2022 | -3.40 Mn |
| Jun 30, 2022 | -3.04 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Dec 31, 2021 | -3.34 Mn |
| Sep 30, 2021 | -7.75 Mn |
| Jun 30, 2021 | -5.81 Mn |